MADD Polyclonal Antibody

Tumor necrosis factor alpha (TNF-alpha) is a signaling molecule that interacts with one of two receptors on cells targeted for apoptosis. The apoptotic signal is transduced inside these cells by cytoplasmic adaptor proteins. MAP kinase-activating death domain protein encoded by MADD is a death domain-containing adaptor protein that interacts with the death domain of TNF-alpha receptor 1 to activate mitogen-activated protein kinase (MAPK) and propagate the apoptotic signal. It is membrane-bound and expressed at a higher level in neoplastic cells than in normal cells. Several transcript variants encoding different isoforms have been described for this gene.

The MADD Polyclonal Antibody is a highly specific and reliable tool for the detection and analysis of MADD protein expression in various biological samples. This antibody is produced using a polyclonal approach, ensuring a diverse range of antibodies that target different epitopes of the MADD protein.

The MADD Polyclonal Antibody has been extensively validated for its specificity and sensitivity in various experimental techniques, including Western blotting, immunohistochemistry, and immunofluorescence. It exhibits minimal cross-reactivity with other proteins, ensuring accurate and precise results.

This antibody is manufactured using state-of-the-art techniques and undergoes rigorous quality control measures to ensure consistent performance and reliability. It is supplied as a ready-to-use solution, eliminating the need for time-consuming and complex antibody preparation procedures.

The MADD Polyclonal Antibody is suitable for use in both research and clinical applications. It enables researchers and clinicians to investigate the role of MADD protein in various physiological and pathological processes, including cancer, diabetes, and neurodegenerative diseases.

With its exceptional specificity, sensitivity, and reliability, the MADD Polyclonal Antibody is an indispensable tool for any researcher or clinician studying the MADD protein.